Skip to Content

Satori Pharmaceuticals to Present Data Highlighting Promise of Gamma-Secretase Modulators in Treatment of Alzheimer's Disease

--Data to be presented at Alzheimer's Association International Conference 2012
--Study selected for oral presentation demonstrates efficacy of Satori's distinct class of gamma-secretase modulators in decreasing AB42 in rodents
--Two poster presentations will discuss new method of determining gamma-secretase selectivity, as well as pharmacokinetic properties of SPI-1865

CAMBRIDGE, Mass., July 10, 2012 /PRNewswire/ -- Satori™ Pharmaceuticals, a company dedicated to developing life-changing therapeutics for Alzheimer's disease (AD), today reported that three abstracts related to the use of gamma-secretase modulators (GSM) in the treatment of AD will be presented at the Alzheimer's Association International Conference (AAIC), being held July 14-19, 2012 in Vancouver, British Columbia.

"These studies add to the growing body of evidence that suggests gamma-secretase modulators are unique compounds that have great potential to be promising new therapies for the treatment of Alzheimer's disease," said Jeff Ives, Ph.D., CEO and Board Member of Satori Pharmaceuticals. "We look forward to sharing our data at AAIC."

Details of Satori's presentations are as follows:

Oral Presentation
Title: Satori gamma-secretase modulators are efficacious in wild type rodents following either acute or steady-state dosing
Session Date and Time: Sunday, July 15, 2012, 3:30 to 5 p.m.
Presentation Number: O1-11-01

Poster Sessions
Title: An improved cell-based method for determining the gamma-secretase enzyme activity against both NOTCH and APP substrates
Session Date and Time: Monday, July 16, 2012, 1 to 3 p.m.
Presentation Number: P2-095

Title: Pharmacokinetic properties of a Satori gamma-secretase modulator, SPI-1865, in multiple animal model systems
Session Date and Time: Wednesday, July 18, 2012, 1 to 3 p.m.
Presentation Number: P4-199

Please note that, pursuant to AAIC's policy, the abstracts for these presentations cannot be disclosed until the officially scheduled date and time of presentation.

About Satori's Gamma-Secretase Modulators
Alzheimer's disease is characterized by the formation of amyloid beta plaques in the brain. Plaques are primarily composed of two main forms of amyloid beta: AB40 and AB42. Satori's program aims to reduce the amount of AB42 in the brain by modulating gamma-secretase, thus lowering brain amyloid, plaque formation and associated damage to normal neuronal function. Studies have demonstrated Satori's proprietary class of gamma-secretase modulators (GSMs) achieve a reduction in AB42 levels without altering total amyloid beta levels in cell lines and animal models of the disease.

About Satori™ Pharmaceuticals
Satori Pharmaceuticals is developing life-changing therapeutics for Alzheimer's disease. Driven by a world-class team of drug development veterans and advisors, Satori is advancing best-in-industry medicines that aim to slow or stop disease progression. Our drug candidates selectively modulate gamma secretase, the enzyme generating the neurotoxic peptides that form amyloid beta plaques – the signature of this debilitating disease. For more information, visit .

SOURCE Satori Pharmaceuticals

CONTACT: Corporate: Jeff Jonker, Satori Pharmaceuticals, +1-415-713-7829,; or Media: Tony Plohoros, 6 Degrees, +1-908-940-0135,

Web Site:


Posted: July 2012